Introduction. Central serous chorioretinopathy (CSC) is an idiopathic disorder which affects young and middle‑aged adults, more often males. Usually it is selflimited but sometimes it becomes chronic. The research is still being carried out to find the most effective way of treatment with the fewest complications. Aim. Evaluating the efficacy of intravitreal injection of ranibizumab in patients with chronic CSC. Methods. 17 eyes of 17 patients qualified for ranibizumab application were treated. Best‑corrected visual acuity, direct ophthalmoscopy, optical coherent tomography (OCT) and fluorescein angiography were performed both during the eligibility visit and during the control visit 1 month after the injection. Results. BCVA improved and central retinal thickness decreased in all patients. Conclusions. Intravitreal injections of ranibizumab can be effective in chronic CSC treatment.